Share Price and Basic Stock Data
Last Updated: November 7, 2025, 6:30 pm
| PEG Ratio | -2.35 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Aspira Pathlab & Diagnostics Ltd operates in the Hospitals & Medical Services industry, with its stock priced at ₹64.3 and a market capitalization of ₹66.2 Cr. The company has shown fluctuating sales figures over recent quarters, with a peak of ₹4.37 Cr in December 2022 before declining to ₹2.60 Cr in June 2023. However, there was a rebound to ₹3.32 Cr in September 2023, indicating a potential recovery. For the fiscal year ending March 2025, sales are reported at ₹22.00 Cr, up from ₹14.46 Cr in March 2023. This growth trajectory is essential for Aspira as it aims to stabilize its revenue streams while navigating the competitive landscape of diagnostics and healthcare services. The trailing twelve months (TTM) revenue stands at ₹22.62 Cr. The company’s revenue per share is ₹21.37, highlighting its ability to generate sales effectively relative to its share count. Overall, while the revenue patterns suggest volatility, the upward trend in annual sales indicates a resilience that could attract investor interest.
Profitability and Efficiency Metrics
<p.Aspira's profitability has shown considerable variability, with operating profit margins (OPM) ranging significantly. The OPM stood at 15.43% for the latest period, yet it faced significant dips in earlier quarters, including a negative OPM of -12.31% in June 2023. The net profit for the fiscal year 2025 is reported at ₹2.07 Cr, representing a recovery from a net loss of ₹0.09 Cr in March 2023. The company’s return on equity (ROE) is a strong 33.6%, well above industry averages, indicating effective utilization of shareholders' funds. However, the return on capital employed (ROCE) has fluctuated, reported at 17.4%, highlighting both efficiency in generating returns and the challenges faced in maintaining consistent profitability. The interest coverage ratio of 11.27x reflects a strong capacity to meet interest obligations, although the negative operating profits in some quarters raise concerns about long-term sustainability. Overall, while Aspira demonstrates strong efficiency metrics, its inconsistent profitability remains a critical focus area.Balance Sheet Strength and Financial Ratios
<p.Aspira's balance sheet presents a mixed picture, with total borrowings reported at ₹8.13 Cr and reserves at -₹3.01 Cr, indicating a reliance on debt financing without sufficient retained earnings to cushion against financial downturns. The debt-to-equity ratio stands at 0.09, suggesting a conservative leverage position compared to industry norms. The current ratio of 2.26 and quick ratio of 2.05 indicate strong liquidity, allowing Aspira to meet its short-term liabilities comfortably. The price-to-book value ratio is recorded at 7.21x, which is relatively high, suggesting that the market values the company significantly above its book value, reflecting investor confidence in future growth prospects. The enterprise value (EV) is noted at ₹86.79 Cr, with an EV to net operating revenue of 3.95x, indicating market expectations for revenue generation. The financial ratios indicate a stable liquidity position but raise questions regarding the effectiveness of debt management and reserve accumulation.Shareholding Pattern and Investor Confidence
<p.Aspira's shareholding structure reveals a noteworthy shift, with promoters holding 18.39% of the shares, a decline from 34.55% in September 2022. This reduction in promoter holding may raise concerns about management confidence in the company’s future prospects. Conversely, public shareholders have increased their stake to 81.62%, reflecting growing retail investor interest. The number of shareholders has risen from 1,141 in September 2022 to 1,770 as of March 2025, indicating a broader base of support for the company. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could suggest limited institutional confidence, which is often critical for stock stability. The public's increasing stake may provide a buffer against volatility, but the diminishing promoter share could be seen as a risk factor, potentially impacting governance and strategic direction.Outlook, Risks, and Final Insight
<p.Aspira Pathlab & Diagnostics Ltd faces a mixed outlook characterized by both strong potential and significant risks. On one hand, the steady increase in annual sales and a robust ROE position the company favorably within its industry. However, the volatility in quarterly profits and the negative reserves pose serious challenges that could affect long-term sustainability. The high reliance on public shareholders without substantial institutional backing may lead to increased stock volatility, particularly if the company encounters operational difficulties. Additionally, the fluctuating operating profit margins suggest that while the company is capable of generating revenue, maintaining profitability remains an elusive goal. If Aspira can stabilize its operations and enhance its profitability metrics, it could leverage its strong market position for future growth. Nevertheless, vigilance regarding cash flow management and strategic investments will be crucial to navigate the inherent risks in the healthcare sector.Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aspira Pathlab & Diagnostics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.9 Cr. | 134 | 195/128 | 6.04 | 115 | 2.61 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.9 Cr. | 23.7 | 36.6/0.00 | 25.5 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.8 Cr. | 12.4 | 21.4/11.6 | 142 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 124 Cr. | 65.9 | 98.7/51.4 | 27.3 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.8 Cr. | 3.86 | 7.70/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 28,585.29 Cr | 855.17 | 70.82 | 100.12 | 0.31% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.97 | 3.71 | 4.37 | 3.41 | 2.60 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 |
| Expenses | 2.79 | 3.25 | 3.56 | 3.26 | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 |
| Operating Profit | 0.18 | 0.46 | 0.81 | 0.15 | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 |
| OPM % | 6.06% | 12.40% | 18.54% | 4.40% | -12.31% | -10.84% | -10.69% | -3.40% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% |
| Other Income | 0.06 | 0.07 | 0.12 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 |
| Interest | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 |
| Depreciation | 0.42 | 0.40 | 0.39 | 0.38 | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 |
| Profit before tax | -0.29 | 0.02 | 0.44 | -0.26 | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.29 | 0.02 | 0.44 | -0.26 | -0.72 | -0.71 | -0.74 | -0.50 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 |
| EPS in Rs | -0.28 | 0.02 | 0.43 | -0.25 | -0.70 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 |
Last Updated: August 19, 2025, 11:05 pm
Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.25 Cr.. The value appears to be declining and may need further review. It has decreased from 5.78 Cr. (Mar 2025) to 5.25 Cr., marking a decrease of 0.53 Cr..
- For Expenses, as of Jun 2025, the value is 4.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.73 Cr. (Mar 2025) to 4.44 Cr., marking a decrease of 0.29 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.81 Cr.. The value appears to be declining and may need further review. It has decreased from 1.05 Cr. (Mar 2025) to 0.81 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Jun 2025, the value is 15.43%. The value appears to be declining and may need further review. It has decreased from 18.17% (Mar 2025) to 15.43%, marking a decrease of 2.74%.
- For Other Income, as of Jun 2025, the value is 0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.37 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.26 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.47 Cr., marking a decrease of 0.25 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.46. The value appears to be declining and may need further review. It has decreased from 0.70 (Mar 2025) to 0.46, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:52 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | 22.62 |
| Expenses | 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 18.65 |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.56 | 3.97 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 17.55% | |||
| Other Income | 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.36 | 0.41 |
| Interest | 0.00 | 0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.35 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.49 |
| Profit before tax | 0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 2.54 |
| Tax % | 57.14% | 25.00% | 0.00% | 0.00% | 0.00% | 0.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 2.56 |
| EPS in Rs | 0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 2.49 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | -9166.67% | -105.15% | 7.17% | 18.15% | 132.55% | 223.19% | -102.02% | -2866.67% | 177.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -9216.67% | 9061.52% | 112.32% | 10.98% | 114.40% | 90.64% | -325.21% | -2764.65% | 3044.19% |
Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 13% |
| 1 Year: | 99% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: October 10, 2025, 3:32 pm
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 0.19 | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | -3.01 |
| Borrowings | 0.00 | 0.00 | 2.62 | 7.29 | 11.36 | 12.52 | 13.80 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 |
| Other Liabilities | 0.03 | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 |
| Total Liabilities | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 |
| Fixed Assets | 0.00 | 0.00 | 0.04 | 7.79 | 7.91 | 8.90 | 8.70 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
| Other Assets | 0.62 | 3.82 | 6.25 | 6.82 | 4.62 | 5.90 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 |
| Total Assets | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 |
Below is a detailed analysis of the balance sheet data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 10.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.29 Cr..
- For Reserves, as of Mar 2025, the value is -3.01 Cr.. The value appears to be improving (becoming less negative). It has improved from -5.08 Cr. (Mar 2024) to -3.01 Cr., marking an improvement of 2.07 Cr..
- For Borrowings, as of Mar 2025, the value is 8.13 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 7.71 Cr. (Mar 2024) to 8.13 Cr., marking an increase of 0.42 Cr..
- For Other Liabilities, as of Mar 2025, the value is 2.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.79 Cr. (Mar 2024) to 2.11 Cr., marking an increase of 0.32 Cr..
- For Total Liabilities, as of Mar 2025, the value is 17.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.71 Cr. (Mar 2024) to 17.52 Cr., marking an increase of 2.81 Cr..
- For Fixed Assets, as of Mar 2025, the value is 6.53 Cr.. The value appears to be declining and may need further review. It has decreased from 6.79 Cr. (Mar 2024) to 6.53 Cr., marking a decrease of 0.26 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 0.13 Cr., marking an increase of 0.13 Cr..
- For Other Assets, as of Mar 2025, the value is 10.86 Cr.. The value appears strong and on an upward trend. It has increased from 7.92 Cr. (Mar 2024) to 10.86 Cr., marking an increase of 2.94 Cr..
- For Total Assets, as of Mar 2025, the value is 17.52 Cr.. The value appears strong and on an upward trend. It has increased from 14.71 Cr. (Mar 2024) to 17.52 Cr., marking an increase of 2.81 Cr..
However, the Borrowings (8.13 Cr.) are higher than the Reserves (-3.01 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.02 | -0.14 | -2.85 | -9.87 | -15.24 | -15.76 | -15.63 | -3.49 | -2.47 | -6.64 | -8.89 | -4.57 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -2,199.61 | -5.86 | -96.03 | -127.01 | 16.32 | 69.30 | 48.72 | 25.16 | 14.10 | |||
| ROCE % | 0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 1.97 |
| Diluted EPS (Rs.) | 1.97 |
| Cash EPS (Rs.) | 3.46 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.82 |
| Revenue From Operations / Share (Rs.) | 21.37 |
| PBDIT / Share (Rs.) | 3.80 |
| PBIT / Share (Rs.) | 2.35 |
| PBT / Share (Rs.) | 2.01 |
| Net Profit / Share (Rs.) | 2.01 |
| NP After MI And SOA / Share (Rs.) | 1.97 |
| PBDIT Margin (%) | 17.79 |
| PBIT Margin (%) | 11.00 |
| PBT Margin (%) | 9.42 |
| Net Profit Margin (%) | 9.42 |
| NP After MI And SOA Margin (%) | 9.19 |
| Return on Networth / Equity (%) | 16.62 |
| Return on Capital Employeed (%) | 16.03 |
| Return On Assets (%) | 11.58 |
| Long Term Debt / Equity (X) | 0.09 |
| Total Debt / Equity (X) | 0.09 |
| Current Ratio (X) | 2.26 |
| Quick Ratio (X) | 2.05 |
| Interest Coverage Ratio (X) | 11.27 |
| Interest Coverage Ratio (Post Tax) (X) | 6.97 |
| Enterprise Value (Cr.) | 86.79 |
| EV / Net Operating Revenue (X) | 3.95 |
| EV / EBITDA (X) | 22.18 |
| MarketCap / Net Operating Revenue (X) | 3.99 |
| Price / BV (X) | 7.21 |
| Price / Net Operating Revenue (X) | 3.99 |
| EarningsYield | 0.02 |
After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.62. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 7.21. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
- Net Profit Margin: 9.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.03% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.62% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.6 (Industry average Stock P/E: 70.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.42%
About the Company - Qualitative Analysis
Aspira Pathlab & Diagnostics Ltd. is a Public Limited Listed company incorporated on 03/07/1973 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L85100MH1973PLC289209 and registration number is 289209. Currently Company is involved in the business activities of Other human health activities. Company's Total Operating Revenue is Rs. 22.00 Cr. and Equity Capital is Rs. 10.29 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086 | info@aspiradiagnostics.com http://www.aspiradiagnostics.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Haseeb Drabu | Chairman & Ind.Director |
| Dr. Pankaj J Shah | Managing Director & CEO |
| Mr. Nikunj Mange | Executive Director |
| Mr. Manas Mengar | Independent Director |
| Mr. Avinash C Mahajan | Independent Director |
| Mrs. Mangala K Prabhu | Independent Director |
FAQ
What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd's intrinsic value (as of 08 November 2025) is 47.69 which is 22.08% lower the current market price of 61.20, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 63.0 Cr. market cap, FY2025-2026 high/low of 107/50.5, reserves of ₹-3.01 Cr, and liabilities of 17.52 Cr.
What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?
The Market Cap of Aspira Pathlab & Diagnostics Ltd is 63.0 Cr..
What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 08 November 2025?
The current stock price of Aspira Pathlab & Diagnostics Ltd as on 08 November 2025 is 61.2.
What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is 107/50.5.
What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?
The Stock P/E of Aspira Pathlab & Diagnostics Ltd is 24.6.
What is the Book Value of Aspira Pathlab & Diagnostics Ltd?
The Book Value of Aspira Pathlab & Diagnostics Ltd is 7.07.
What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?
The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.
What is the ROCE of Aspira Pathlab & Diagnostics Ltd?
The ROCE of Aspira Pathlab & Diagnostics Ltd is 17.4 %.
What is the ROE of Aspira Pathlab & Diagnostics Ltd?
The ROE of Aspira Pathlab & Diagnostics Ltd is 33.6 %.
What is the Face Value of Aspira Pathlab & Diagnostics Ltd?
The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.